Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Image
  • Published:

Infographic: five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (DRCR Protocol T Extension Study)

Eye (2026)Cite this article

Subjects

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. NIHR Biomedical Research Centre, Moorfields Eye Hospital NHS Foundation Trust, London, UK

    Eleonora Riotto, Francesca Lamanna & Livia Faes

  2. Ophthalmology Department, Royal Derby Hospital NHS Foundation Trust, London, UK

    Venughanan Manikavasagar

  3. Cantonal Hospital Winterthur, Zürich, Switzerland

    Livia Faes

  4. University of Zurich Epidemiology, Biostatistics & Prevention Institute (EBPI), Zürich, Switzerland

    Livia Faes

  5. Ophthalmology Department, Moorfields Eye Hospital NHS Foundation Trust, London, UK

    Dun Jack Fu

Authors
  1. Eleonora Riotto
    View author publications

    Search author on:PubMed Google Scholar

  2. Francesca Lamanna
    View author publications

    Search author on:PubMed Google Scholar

  3. Venughanan Manikavasagar
    View author publications

    Search author on:PubMed Google Scholar

  4. Livia Faes
    View author publications

    Search author on:PubMed Google Scholar

  5. Dun Jack Fu
    View author publications

    Search author on:PubMed Google Scholar

Contributions

ER—conceptualisation and design. VM—design. FL—reviewed, fed back and approved final infographic. LF—reviewed, fed back and approved final infographic. DJF—reviewed, fed back and approved final infographic.

Corresponding author

Correspondence to Eleonora Riotto.

Ethics declarations

Competing interests

DJF - Consulting fees and/or research support from Abbvie, Allergan, Apellis, Boehringer Ingelheim, Galimedix, Google Health, NIHR, Wellcome Trust, Roche; member of Eye editorial board. Livia Faes - Research support from Bayer AG, F Hoffman-La, Roche, AG and Abbvie, and meetings and travel support from Apellis Pharmaceuticals Inc; member of Eye editorial board.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Riotto, E., Lamanna, F., Manikavasagar, V. et al. Infographic: five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (DRCR Protocol T Extension Study). Eye (2026). https://doi.org/10.1038/s41433-026-04321-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41433-026-04321-7

Search

Advanced search

Quick links